Pancreatic cancer is one of the most lethal cancers due to its late diagnosis and aggressive progression. Traditional imaging and pathology often miss early molecular events, leaving few options for early intervention.

The Pancreas Immunocarcinogenic Assay evaluates immune system activity and prometastatic biomarker patterns linked to pancreatic carcinogenesis. By analyzing these molecular signals, this test enables earlier risk identification, therapy guidance, and recurrence monitoring, even in patients without advanced symptoms.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Pancreas Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Earlier Detection Support

Identifies immune and molecular activity that precedes clinical presentation.

Precision Oncology Guidance

Provides biomarker insights to guide targeted therapy and immunotherapy selection.

Monitoring Capability

Tracks molecular shifts during treatment and remission to assess effectiveness.

Complementary Evidence

Enhances imaging and pathology with immune-molecular context.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Pancreas Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and pancreatic tumor progression:

  • Immune checkpoint activity (PD-L1, CTLA-4 pathways)

  • Tumor-promoting cytokines and chemokines (IL-6, IL-8, TNF-α)

  • Angiogenesis drivers (VEGF, FGF) linked to tumor growth

  • Tumor microenvironment signals promoting invasion and metastasis

  • Stress and metabolic biomarkers associated with pancreatic tumor biology

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through Persona Biomed’s secure portal.

02

Sample Collection

Blood draw performed at a certified lab or mobile phlebotomy.

03

Laboratory Analysis

Molecular assays quantify immune and prometastatic biomarkers.

04

Results Delivery

Physician-ready report delivered through the portal, with AI-powered patient-friendly summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Individuals with a family history of pancreatic cancer or genetic predisposition (e.g., BRCA mutations).

  • Patients with suspicious imaging or clinical findings requiring deeper molecular insight.

  • Individuals at risk due to lifestyle or comorbidities (chronic pancreatitis, diabetes, obesity).

  • Patients in treatment or remission requiring biomarker-based monitoring.

Register Now for Pancreas Immunocarcinogenic Assay

Register now for the Pancreas Immunocarcinogenic Assay to uncover hidden immune and molecular signals of pancreatic cancer and guide proactive treatment.

Register now